Investigations of outbreaks of multidrug-resistant tuberculosis have found low rates of treatment response and very high mortality, and they have mainly involved patients with advanced human immunodeficiency virus (HIV) infection.
For patients without HIV infection, one study reported an overall rate of response to treatment of 56 percent, and the mortality from tuberculosis was 22 percent.
We investigated treatment response and mortality rates in 26 HIV-negative patients in New York with multidrug-resistant tuberculosis.
Between March 1991 and September 1994,26 HIV-negative patients were identified and treated.
Of the 25 patients for whom adequate data were available for analysis, 24 had clinical responses ; all 17 patients for whom data on microbiologic response were available had such a response.
Side effects requiring the discontinuation of medication occurred in 4 of 23 patients who were treated with second-line antituberculosis medications.
The median follow-up for the 23 patients who responded and who received appropriate therapy was 91 weeks.
In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically.
(N Engl J Med 1995 ; 333 : 907-11.).
Mots-clés Pascal : Tuberculose, Mycobactériose, Bactériose, Infection, Poumon, Antituberculeux, Résistance traitement, Exploration bactériologique, Etats Unis, Amérique du Nord, Amérique, Exploration, Epidémiologie, Adulte, Homme, New York, Appareil respiratoire pathologie, Poumon pathologie, Chimiothérapie
Mots-clés Pascal anglais : Tuberculosis, Mycobacterial infection, Bacteriosis, Infection, Lung, Antituberculous agent, Negative therapeutic reaction, Bacteriological investigation, United States, North America, America, Exploration, Epidemiology, Adult, Human, New York, Respiratory disease, Lung disease, Chemotherapy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0571148
Code Inist : 002B05B02E. Création : 01/03/1996.